These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 20386529)

  • 41. Neural transplantation.
    Bakay RA
    J Neurosurg; 2005 Jul; 103(1):6-8; discussion 8. PubMed ID: 16121966
    [No Abstract]   [Full Text] [Related]  

  • 42. Recent developments in the design of phase II clinical trials.
    Thall PF; Simon RM
    Cancer Treat Res; 1995; 75():49-71. PubMed ID: 7640167
    [No Abstract]   [Full Text] [Related]  

  • 43. P-values, survival analyses and phase II trials.
    Fayers P
    Br J Cancer; 1994 Jun; 69(6):1182-3. PubMed ID: 8043122
    [No Abstract]   [Full Text] [Related]  

  • 44. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 45. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 46. Controversies in the design of phase II clinical trials.
    Seymour L
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):95-7. PubMed ID: 20386529
    [No Abstract]   [Full Text] [Related]  

  • 47. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 50. Systemic therapy for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Pu YS; Vogelzang NJ
    BJU Int; 2008 Apr; 101(7):795-803. PubMed ID: 18070193
    [No Abstract]   [Full Text] [Related]  

  • 51. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls.
    Abdel-Rahman SM; Reed MD; Wells TG; Kearns GL
    Clin Pharmacol Ther; 2007 Apr; 81(4):483-94. PubMed ID: 17329988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions.
    Wagner LI; Wenzel L; Shaw E; Cella D
    J Clin Oncol; 2007 Nov; 25(32):5058-62. PubMed ID: 17991921
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.